INOVIO Seeks EU Approval for VOCERYQ Immunotherapy

The company has applied to the European Medicines Agency to treat recurrent respiratory papillomatosis, a rare disease caused by HPV types 6 and 11.

Updated on Nov. 22, 2026 in Biotech

Bold flat-color vector editorial illustration of a clear unlabeled glass vial beside a loose coil of translucent strand on a teal surface, evoking a DNA-based immunotherapy.
INOVIO has applied to the European Medicines Agency for conditional authorization of VOCERYQ, a plasmid DNA immunotherapy for recurrent respiratory papillomatosis, after its U.S. accelerated approval. AI Illustration. Upload story photo >

INOVIO Pharmaceuticals has applied to the European Medicines Agency for conditional marketing authorization of VOCERYQ, a plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis. The U.S. Food and Drug Administration granted VOCERYQ accelerated approval on October 30, 2026, as the first plasmid DNA-based immunotherapy the agency has approved.

Why it matters

Recurrent respiratory papillomatosis frequently returns after surgical removal, forcing repeated procedures that can damage the vocal cords. A conditional European authorization would extend access to a treatment aimed at reducing how often those surgeries are needed.

VOCERYQ is administered with the CELLECTRA 5PSP delivery device, which carries a CE mark, across a nine-week dosing regimen that follows surgical removal of visible papillomas. European regulators have certified its chemistry, manufacturing and controls data, but the agency's decision on conditional authorization remains pending.

The players

INOVIO Pharmaceuticals

INOVIO Pharmaceuticals is a Plymouth Meeting, Pennsylvania-based biotechnology company developing DNA-based immunotherapies and the CELLECTRA delivery device.

U.S. Food and Drug Administration

The U.S. Food and Drug Administration is the federal agency responsible for regulating drugs, biologics and medical devices in the United States.

European Medicines Agency

The European Medicines Agency is the European Union body that evaluates and supervises medicines for the European market.

The details

VOCERYQ is designed to stimulate an immune response against HPV-6 and HPV-11 antigens, the viral types primarily responsible for the disease. Treatment begins with surgical removal of visible papillomas before the first administration, and the European Commission granted the product orphan drug designation in 2023.

Timeline

  1. 2023: European Commission grants orphan drug designation to VOCERYQ.

  2. 2025: Supporting results are published in Nature Communications and The Laryngoscope.

  3. October 30, 2026: FDA grants accelerated approval to VOCERYQ.

  4. October 2026: Long-term efficacy findings are published in The Laryngoscope.

  5. First quarter of 2027: Full U.S. commercial launch is planned.

The Tech Race

VOCERYQ is the first plasmid DNA-based immunotherapy the FDA has approved, placing a DNA platform technology on the regulatory path that previously cleared other drug classes. Its pursuit of European conditional authorization follows the same accelerated pathway logic that U.S. regulators applied on October 30, 2026.

Patients with recurrent respiratory papillomatosis may gain access to a treatment intended to reduce repeated surgeries if European authorization is granted. The U.S. launch timeline depends on ordering availability about 60 days after approval, with a full commercial launch planned for early 2027.

The takeaway

A plasmid DNA immunotherapy has cleared FDA accelerated approval for a rare airway disease, and its European review will show whether that regulatory path travels across the Atlantic. Patients facing repeated surgeries should discuss the approved treatment option with their clinicians as availability expands.

What happens next

The European Medicines Agency will review INOVIO's application for conditional marketing authorization, and U.S. ordering is expected to open about 60 days after the FDA's October 30, 2026 approval.

Further reading

Explore more biotech developments shaping drug approvals and therapies.

More information

Read the VOCERYQ product information on the manufacturer's website.

Source note: This article includes information reported by MyChesCo.